A quick-release formulation of lornoxicam, a potent NSAID from the chemical class of oxicams, offers a faster onset of pain relief compared with the standard tablet formulation. Methods ...

Lornoxicam is a strong analgesic and anti-inflammatory NSAID with balanced cyclo-oxygenase (COX)-1/COX-2 inhibition and excellent tolerability. In the course of the development of selective COX-2 ...

Researchers followed 11,745 adults over 14.5 years and found that those who used NSAIDs long-term had a 12% reduced dementia risk. However, short- and intermediate-term NSAID use did not provide the ...

No association seen for cumulative nonsteroidal anti-inflammatory drug dose with reduced dementia risk. HealthDay News — Long-term nonsteroidal anti-inflammatory drug (NSAID) use is associated ...

NSAID use was associated with lower dementia risk for long-term users and with elevated risk for short-term and intermediate-term use. (HealthDay News) — Long-term nonsteroidal anti-inflammatory ...

Long-term NSAID use was associated with a 12% reduced risk of developing dementia. Short- and intermediate-term use did not provide benefits. Also, the cumulative dose of NSAIDs was not associated ...

It is involved in kidney and platelet function as well. Because of these roles, drugs that inhibit COX-1 can cause unwanted side effects. COX-2 inhibitors are a type of NSAID that selectively blocks ...

Other NSAIDs do not have this effect. Cox-2 inhibitors are a newer form of prescription NSAID. As you might guess, they only affect Cox-2 enzymes and not Cox-1. Two of them -- Bextra and Vioxx ...

Of the study participants, 9,520 (81%) had used NSAIDs at any given time, based on pharmacy dispensing records, and 2,091 developed dementia. Long-term NSAID use was associated with a lower risk of ...